A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Quantum computing is shaping up to be the next big investing revolution, and for a very good reason. With the power to solve ...

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector ...